国家医保局局长章轲：支持国产医药产品走向世界

Core Viewpoint - The Chinese government is focusing on reforming the national medical insurance system during the "14th Five-Year Plan" period, emphasizing the need for collaboration between various healthcare sectors and the promotion of domestic pharmaceutical products globally [1][2][3]. Group 1: Medical Insurance Reform - The National Healthcare Security Administration (NHSA) plans to establish a collaborative mechanism for procurement and payment reforms, aiming to reshape the funding allocation ecosystem through prepayment and direct settlement systems [1]. - During the "14th Five-Year Plan," the cumulative expenditure of the medical insurance fund exceeded 13 trillion yuan, benefiting nearly 20 billion patient visits, which highlights the significant financial support for healthcare institutions and the promotion of deep reforms in the healthcare service supply side [2]. - The NHSA aims to enhance the management of the medical insurance catalog, conducting comprehensive value assessments of drugs and dynamically adjusting the catalog to support genuine and differentiated innovations [2]. Group 2: Support for Innovative Drugs - The NHSA has introduced several measures to support the high-quality development of innovative drugs, including a comprehensive support system covering research, access, usage, and payment [3]. - A new drug price registration system has been launched to provide a transparent platform for global drug pricing, facilitating the international promotion of Chinese innovative drugs and attracting high-quality foreign drugs to the Chinese market [4]. - The NHSA is organizing a negotiation for the 2025 National Basic Medical Insurance Drug Catalog and the Commercial Health Insurance Innovative Drug Catalog, with participation from 120 domestic and foreign enterprises [3].